Research

Hormonal

Deprescribing GLP-1 agonists in patients with Type 2 Diabetes does not result in weight regain or loss of glycemic control if the patient maintains Carbohydrate Restricted Nutrition Therapy (CRNT) supported by continuous remote care.

If you are taking a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes, you may be able to stop the medication without regaining weight or losing blood sugar control, provided you switch to a strict low-carbohydrate diet (under 30g carbs/day) and maintain nutritional ketosis. This approach mimics the drug's hormonal effects on hunger and satiety. You should work with a healthcare provider to monitor your progress and determine if you are a candidate for deprescription.

ModerateSupportsMEDIUM confidence
Results of this real-world analysis demonstrate that GLP-1 can be discontinued without weight regain following initiation of successful co-therapy with carbohydrate restricted nutrition within this care model.
Amy L. McKenzie et al. · Diabetes Therapy · 2024

Why this rating

Real-world retrospective propensity-matched cohort study; high ecological validity but lower internal validity than RCTs.

Source

Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study

Amy L. McKenzie et al. · Diabetes Therapy · 2024

DOI 10.1007/s13300-024-01547-0

cohort · n=308Cited 16×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →